138 related articles for article (PubMed ID: 32904337)
1. Vorinostat-loaded titanium oxide nanoparticles (anatase) induce G2/M cell cycle arrest in breast cancer cells via
Abdel-Ghany S; Raslan S; Tombuloglu H; Shamseddin A; Cevik E; Said OA; Madyan EF; Senel M; Bozkurt A; Rehman S; Sabit H
3 Biotech; 2020 Sep; 10(9):407. PubMed ID: 32904337
[TBL] [Abstract][Full Text] [Related]
2. Vorinostat induces G2/M cell cycle arrest in breast cancer cells via upregulation of PTEN.
Alqosaibi AI; Abdel-Ghany S
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1503-1511. PubMed ID: 36876690
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat enhances the therapeutic potential of Erlotinib via MAPK in lung cancer cells.
Alqosaibi AI; Abdel-Ghany S; Al-Mulhim F; Sabit H
Cancer Treat Res Commun; 2022; 30():100509. PubMed ID: 35026535
[TBL] [Abstract][Full Text] [Related]
4. Differential Mechanisms of Cell Death Induced by HDAC Inhibitor SAHA and MDM2 Inhibitor RG7388 in MCF-7 Cells.
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rathinavelu A
Cells; 2018 Dec; 8(1):. PubMed ID: 30583560
[TBL] [Abstract][Full Text] [Related]
5. Sensitizing Triple Negative Breast Cancer to Tamoxifen Chemotherapy via a Redox-Responsive Vorinostat-containing Polymeric Prodrug Nanocarrier.
Ma W; Sun J; Xu J; Luo Z; Diao D; Zhang Z; Oberly PJ; Minnigh MB; Xie W; Poloyac SM; Huang Y; Li S
Theranostics; 2020; 10(6):2463-2478. PubMed ID: 32194813
[TBL] [Abstract][Full Text] [Related]
6. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
[TBL] [Abstract][Full Text] [Related]
7. Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer.
Wu PF; Gao WW; Sun CL; Ma T; Hao JQ
Chin Med J (Engl); 2020 Jun; 133(11):1304-1311. PubMed ID: 32452893
[TBL] [Abstract][Full Text] [Related]
8. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
You BR; Han BR; Park WH
Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
[TBL] [Abstract][Full Text] [Related]
10. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice.
Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK
Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267
[TBL] [Abstract][Full Text] [Related]
11. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable Eri silk nanoparticles as a delivery vehicle for bovine lactoferrin against MDA-MB-231 and MCF-7 breast cancer cells.
Roy K; Patel YS; Kanwar RK; Rajkhowa R; Wang X; Kanwar JR
Int J Nanomedicine; 2016; 11():25-44. PubMed ID: 26730188
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression.
Reguart N; Rosell R; Cardenal F; Cardona AF; Isla D; Palmero R; Moran T; Rolfo C; Pallarès MC; Insa A; Carcereny E; Majem M; De Castro J; Queralt C; Molina MA; Taron M
Lung Cancer; 2014 May; 84(2):161-7. PubMed ID: 24636848
[TBL] [Abstract][Full Text] [Related]
14. Efficient new constructs against triple negative breast cancer cells: synthesis and preliminary biological study of ferrocifen-SAHA hybrids and related species.
Cázares Marinero Jde J; Lapierre M; Cavaillès V; Saint-Fort R; Vessières A; Top S; Jaouen G
Dalton Trans; 2013 Nov; 42(43):15489-501. PubMed ID: 24030275
[TBL] [Abstract][Full Text] [Related]
15. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment.
Huang L; Pardee AB
Mol Med; 2000 Oct; 6(10):849-66. PubMed ID: 11126200
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer combination therapy: Hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab.
Pang J; Xing H; Sun Y; Feng S; Wang S
Biomed Pharmacother; 2020 May; 125():109861. PubMed ID: 32070872
[TBL] [Abstract][Full Text] [Related]
17. A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.
Han L; Wang T; Wu J; Yin X; Fang H; Zhang N
Int J Nanomedicine; 2016; 11():6003-6022. PubMed ID: 27956831
[TBL] [Abstract][Full Text] [Related]
18. SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
Bellarosa D; Bressan A; Bigioni M; Parlani M; Maggi CA; Binaschi M
Int J Oncol; 2012 Oct; 41(4):1486-94. PubMed ID: 22797667
[TBL] [Abstract][Full Text] [Related]
19. Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.
Shi XY; Ding W; Li TQ; Zhang YX; Zhao SC
Med Sci Monit; 2017 Dec; 23():5793-5802. PubMed ID: 29211704
[TBL] [Abstract][Full Text] [Related]
20. Role of Zn doping in oxidative stress mediated cytotoxicity of TiO2 nanoparticles in human breast cancer MCF-7 cells.
Ahamed M; Khan MA; Akhtar MJ; Alhadlaq HA; Alshamsan A
Sci Rep; 2016 Jul; 6():30196. PubMed ID: 27444578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]